Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel.